The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates
Thierry Facon
• 14 Jun 2019
Thierry Facon, MD, Lille University Hospital, Lille, France, gives us an update on the CASSIOPEIA study (NCT02541383), which evaluated daratumumab in transplant-eligible patients with previously untreated multiple myeloma. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Dr Facon also gives us an update on other trials, such as MAIA (NCT02252172), and COLUMBA (NCT03277105).
